Impact of immunoprophylaxis with palivizumab on respiratory syncytial virus infection in preterm infants less than 35 weeks in Colombian hospitals
Sign Up to like & getrecommendations! Published in 2022 at "Pediatric Pulmonology"
DOI: 10.1002/ppul.26051
Abstract: To evaluate the impact of immunoprophylaxis with palivizumab in preterm infants less than 35 weeks in terms of hospitalization rate, intensive care unit requirement, and mortality. read more here.
Keywords: palivizumab respiratory; infants less; less weeks; impact immunoprophylaxis ... See more keywords
Incidence of respiratory syncytial virus infection in children with congenital heart disease undergoing immunoprophylaxis with palivizumab in Pará state, north region of Brazil
Sign Up to like & getrecommendations! Published in 2019 at "BMC Pediatrics"
DOI: 10.1186/s12887-019-1681-6
Abstract: BackgroundPalivizumab prophylaxis for the human respiratory syncytial virus (HRSV) has been reported to reduce the risk of hospital admissions related to HRSV in children with congenital heart disease (CHD). These children are at high risk… read more here.
Keywords: immunoprophylaxis palivizumab; hrsv; respiratory syncytial; infection ... See more keywords